Rendimiento del HE4 en el diagnóstico, pronóstico y predicción de recidiva en cáncer de endometrio.
HE4 performance in the diagnosis, prognosis and prediction of relapse in endometrial cancer.
Barra lateral del artículo
PDF
FLIP
Contenido principal del artículo
Resumen
Introducción: el cáncer de endometrio es un cáncer ginecológico frecuente. La biopsia de endometrio es la prueba de oro para el diagnóstico. Ningún biomarcador ha mostrado relevancia clínica hasta el momento. El HE4 parece ser de alta sensibilidad y especificidad, incluso en los estadios tempranos. Objetivos: analizar la evidencia médica publicada hasta la fecha sobre el potencial valor del HE4 como prueba diagnóstica, al igual que su utilidad en lo concerniente al pronóstico y recaída en las pacientes con cáncer de endometrio. Materiales y métodos: se realizó revisión narrativa de la literatura en las bases de datos Pubmed-Medline y EMBASE desde 1990 a 2016. La búsqueda se estructuró utilizando términos MESH. Resultados: los resultados de sensibilidad varían según los diferentes puntos de cortes de HE4 entre 41% y 94%, especificidad entre 36% y 100%. El punto de corte que mejor rendimiento mostró fue 70 pmol/L, con sensibilidad de 59.4% y especificidad de 100%. En pronóstico, los estudios muestran que el HE4 puede ayudar en la predicción del riesgo de invasión miometrial, para la adecuada estatificación, así como definición del compromiso extrauterino y ganglionar para determinar de una manera más acertada la necesidad de linfadenectomía. Conclusión: resultados iniciales sugieren que el HE4 es un biomarcador que puede ser útil en el diagnóstico de las mujeres con cáncer de endometrio, además puede identificar aquellas con alto riesgo de recurrencia y puede ser utilizado en el seguimiento y detección de esta.
Palabras clave:
Descargas
Detalles del artículo
Referencias (VER)
Bie Y, Zhang Z. Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis. World J Surg Oncol. 2014; 12:169. https://doi.org/10.1186/1477-7819-12-169
NCCN. Clinical practice gidelines in oncology. Uterine Neoplasms version 2.2016 2016.
World Health Organization, International Agency for Research on Cancer. Globocan 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012 [Internet]. Geneve: The Organization; 2015 [cited 2015/11/05]. Available from: http://globocan.iarc.fr/Default.aspx
Pardo-Ramos C, Cendales-Duarte R. Incidencia, mortalidad y prevalencia de cáncer en Colombia, 2007-2011. Instituto Nacional de Cancerología. 2015.
Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, et al. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol. 2014; 134(2): 385-92. https://doi.org/10.1016/j.ygyno.2014.05.018
Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997; 89(15): 1110-6. https://doi.org/10.1093/jnci/89.15.1110
Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994; 86(7): 527-37. https://doi.org/10.1093/jnci/86.7.527
Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006; 106(11): 2376-81. https://doi.org/10.1002/cncr.21866
Soler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, la Vecchia C. Hypertension and hormone-related neoplasms in women. Hypertension. 1999; 34(2): 320-5. https://doi.org/10.1161/01.HYP.34.2.320
McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. Am J Epidemiol. 1996; 143(12): 1195-202. https://doi.org/10.1093/oxfordjournals.aje.a008707
Timmermans A, Opmeer BC, Khan KS, Bachmann LM, Epstein E, Clark TJ, et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2010; 116(1): 160-7. https://doi.org/10.1097/AOG.0b013e3181e3e7e8
Epstein E, Ramirez A, Skoog L, Valentin L. Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding. Acta Obstet Gynecol Scand. 2001; 80(12): 1131-6. https://doi.org/10.1034/j.1600-0412.2001.801210.x
Dijkhuizen FP, Mol BW, Brölmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000; 89(8): 1765-72. https://doi.org/10.1002/1097-0142(20001015)89:81765::AID-CNCR173.0.CO;2-F
Connor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma. Obstet Gynecol. 2000; 95(5): 692-96. https://doi.org/10.1097/00006250-200005000-00012
Kitajima K, Murakami K, Yamasaki E, Kaji Y, Sugimura K. Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. Eur Radiol. 2009; 19(6): 1529-36. https://doi.org/10.1007/s00330-008-1271-8
Omer B, Genc S, Takmaz O, Dirican A, Kusku-Kiraz Z, Berkman S, et al. The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients. Tumour Biol. 2013; 34(5): 2645-50. https://doi.org/10.1007/s13277-013-0814-z
Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008; 110(2): 196-201. https://doi.org/10.1016/j.ygyno.2008.04.002
Zanotti L, Bignotti E, Calza S, Bandiera E, Ruggeri G, Galli C, et al. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin Chem Lab Med. 2012; 50(12): 2189-98. https://doi.org/10.1515/cclm-2011-0757
Jiang SW, Chen H, Dowdy S, Fu A, Attewell J, Kalogera E, et al. HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival. Int J Mol Sci. 2013; 14(11): 22655-77. https://doi.org/10.3390/ijms141122655
Galgano MT, Hampton GM, Frierson HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006; 19(6): 847-53. https://doi.org/10.1038/modpathol.3800612
Zhang AM, Zhang P. [Clinical value of combined detection of serum human epididymal secretory protein E4 and CA (125) in the diagnosis of endometrial carcinoma]. Zhonghua Fu Chan Ke Za Zhi. 2012; 47(2): 125-8.
Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, et al. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study. Tumour Biol. 2013; 34(1): 571-6. https://doi.org/10.1007/s13277-012-0583-0
Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer. 2011; 104(9): 1418-25. https://doi.org/10.1038/bjc.2011.109
Kemik P, Saatli B, Yıldırım N, Kemik VD, Deveci B, Terek MC, et al. Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer. Gynecol Oncol. 2016; 140(1): 64-9. https://doi.org/10.1016/j.ygyno.2015.11.020
Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol. 2012; 124(2): 270-5. https://doi.org/10.1016/j.ygyno.2011.10.025
Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, Kinalski M, Terlikowski SJ. Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy. Adv Med Sci. 2016; 61(1): 23-7. https://doi.org/10.1016/j.advms.2015.07.010
Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, et al. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol. 2012; 126(2): 186-91. https://doi.org/10.1016/j.ygyno.2012.04.022
Saarelainen SK, Peltonen N, Lehtimäki T, Perheentupa A, Vuento MH, Mäenpää JU. Predictive value of serum human epididymis protein 4 and cancer antigen 125 concentrations in endometrial carcinoma. Am J Obstet Gynecol. 2013; 209(2): 142.e1-6. https://doi.org/10.1016/j.ajog.2013.04.014
Antonsen SL, Høgdall E, Christensen IJ, Lydolph M, Tabor A, Loft Jakobsen A, et al. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Acta Obstet Gynecol Scand. 2013; 92(11): 1313-22. https://doi.org/10.1111/aogs.12235
Capriglione S, Plotti F, Miranda A, Ricciardi R, Scaletta G, Aloisi A, et al. Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study. Tumour Biol. 2015; 36(6): 4151-6. https://doi.org/10.1007/s13277-015-3049-3
Brennan DJ, Hackethal A, Metcalf AM, Coward J, Ferguson K, Oehler MK, et al. Serum HE4 as a prognostic marker in endometrial cancer a population based study. Gynecol Oncol. 2014; 132(1): 159-65. https://doi.org/10.1016/j.ygyno.2013.10.036
Moore RG, Miller CM, Brown AK, Robison K, Steinhoff M, Lambert-Messerlian G. Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer. 2011; 21(7): 1185-90. https://doi.org/10.1097/IGC.0b013e3182229ad8
Minar L, Klabenesova I, Jandakova E, Zlamal F, Bienertova-Vasku J. Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging. J Obstet Gynaecol Res. 2015; 41(10): 1644-52. https://doi.org/10.1111/jog.12764
Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008; 100(23): 1707-16. https://doi.org/10.1093/jnci/djn397
Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK, group As. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009; 373(9658): 125-36. https://doi.org/10.1016/S0140-6736(08)61766-3
Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010; 375(9721): 1165-72. https://doi.org/10.1016/S0140-6736(09)62002-X
Angioli R, Capriglione S, Scaletta G, Aloisi A, Miranda A, De Cicco Nardone C, et al. The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program. Tumour Biol. 2016; 37(4): 4973-78. https://doi.org/10.1007/s13277-015-4324-z
Brennan DJ, Hackethal A, Mann KP, Mutz-Dehbalaie I, Fiegl H, Marth C, et al. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. BMC Cancer. 2015; 15:33. https://doi.org/10.1186/s12885-015-1028-0
Citado por
